araag2/HINT huggingface dataset:
Clinical trial NCT00128102 (phase 3, status: completed)
Conditions: mesothelioma, lung cancer
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vorinostat, placebo
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria :

          -  18 years or older with confirmed diagnosis of malignant pleural mesothelioma

          -  In countries where pemetrexed is an approved mesothelioma treatment, the participant's
             disease has progressed or relapsed following treatment with at least one prior
             chemotherapy regimen with pemetrexed and either cisplatin or carboplatin OR in
             countries where pemetrexed is not approved for mesothelioma, the participant's disease
             has progressed or relapsed following treatment with at least one prior chemotherapy
             regimen OR pemetrexed is not the preferred therapy for the participant and the
             participant's disease has progressed or relapsed following treatment with at least one
             prior chemotherapy regimen

          -  Received no more than 2 prior systemic therapy regimens

          -  Karnofsky performance scale status of ≥70

          -  Has adequate bone marrow, liver, and kidney function and adequate coagulation (per
             prespecified laboratory values)

        Extension Phase Inclusion Criteria:

          -  Participants who are receiving treatment with vorinostat and have not experienced
             progression of mesothelioma

          -  Randomized to the placebo arm and: 1) have a Karnofsky performance scale status of
             ≥70; and 2) have adequate bone marrow, liver, and kidney function and adequate
             coagulation (per prespecified laboratory values)

          -  Randomized to vorinostat and have discontinued study therapy for reasons other than
             progression of mesothelioma, if the investigator is of the opinion that the potential
             benefit outweighs potential risks associated with using vorinostat

        Exclusion Criteria:

          -  Has an active infection for which they received treatment with intravenous antibiotic,
             antiviral, or antifungal medications within 2 weeks of the start of study drug.

          -  Has a "currently active" second malignancy; a malignancy is not considered "currently
             active" if participants have completed therapy for the second malignancy and are
             disease free from prior malignancies for >5 years

          -  Has uncontrolled brain metastases

          -  Has a known human immunodeficiency virus (HIV) infection or HIV-related malignancy

          -  Is pregnant or breast feeding

          -  Has a history of gastrointestinal surgery or other procedures that might interfere
             with the absorption or swallowing of the study drug
Clinical trial NCT01012765 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol, tiotropium, placebo
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Co-operative outpatients with a diagnosis of COPD (moderate as classified by the GOLD
             Guidelines, 2008) and including:

               -  Smoking history of at least 10 pack years

               -  Post-bronchodilator FEV1 <80% and ≥50% of the predicted normal value (Visit 2).

               -  Post-bronchodilator FEV1/forced vital capacity (FVC) <70% (Visit 2).

        Exclusion Criteria:

          -  Patients who received any corticosteroid (including inhaled) for 3 months prior to
             screening

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00254202 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: iloperidone, active comparator, placebo
SMILES: COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with schizophrenia.

          -  Subject must sign a written consent form.

        Exclusion Criteria:

          -  Clinically significant disease of the heart, kidneys, liver or gastrointestinal system

          -  Psychiatric disorder other than schizophrenia
Clinical trial NCT01197508 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: tc-5214, placebo
SMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  The patient must have a clinical diagnosis of major depressive disorder (MDD) with
             inadequate response to no more than one antidepressant.

          -  Outpatient status at enrollment and randomization.

        Exclusion Criteria:

          -  Patients with a lifetime history of bipolar disorder, psychotic disorder or
             post-traumatic stress disorder.

          -  Patients with a history of suicide attempts in the past year and/or seen by the
             investigator as having a significant history of risk of suicide or homicide.

          -  History of renal insufficiency or impairment or conditions that could affect
             absorption or metabolism of investigational product.
Clinical trial NCT00409409 (phase 3, status: completed)
Conditions: allergy
ICD codes: T78.40XS, T78.49XS, Z91.010, Z91.012, Z91.013, Z91.030, Z91.040
Drugs: 300 ir grass pollen allergen extract tablet, placebo tablet
SMILES: CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients aged 5 to 17 years.

          -  Written consent / assent.

          -  Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen
             seasons.

          -  Sensitised to grass pollen (positive SPT and grass pollen-specific IgE values of at
             least Class 2).

          -  Total symptom score on the Retrospective RTSS during the previous pollen season of
             greater than or equal to 12.

        Exclusion Criteria:

          -  Patients who have received any desensitisation treatment for grass pollen.
Clinical trial NCT01040728 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: olodaterol (bi1744) low, olodaterol (bi1744) high, tiotropium 18 mcg, placebo (for olodaterol (bi1744)l), placebo (for tiotropium)
SMILES: COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients willing to participate with confirmed diagnosis of COPD

          -  40 years of age or older

          -  having a 10 pack year smoking history

          -  able to perform serial pulmonary function tests

          -  able to use both a Dry powder inhaler (DPI) and Respimat device

        Exclusion criteria:

          -  Significant other disease

          -  clinically relevant abnormal hematology, chemistry, or urinalysis

          -  history of asthma

          -  diagnosis of thyrotoxicosis

          -  paroxysmal tachycardia related to beta agonists

          -  history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure
             within 1 year

          -  active tuberculosis, cystic fibrosis, clinically evident bronchiectasis

          -  significant alcohol or drug abuse

          -  pulmonary resection

          -  taking oral beta adrenergics

          -  taking unstable oral steroids

          -  daytime oxygen

          -  enrolled in rehabilitation program

          -  enrolled in another study or taking investigational products

          -  pregnant or nursing women, women of child bearing potential not willing to use two
             methods of birth control

          -  those who are not willing to comply with pulmonary medication washouts
Clinical trial NCT00522834 (phase 3, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: elesclomol (sta-4783), paclitaxel
SMILES: CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C1=CC=CC=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin

          -  ECOG performance status of <=2

          -  Measurable disease according to modified RECIST

          -  Life expectancy of greater than 12 weeks

          -  LDH <= 2.0 x ULN

          -  Clinical lab values within protocol parameters.

          -  At least 18 years old and able and willing to provide informed consent to participate

        Exclusion Criteria:

          -  Previous cytotoxic chemotherapy treatment for melanoma

          -  Received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy,
             vaccine or investigational non-chemotherapeutic treatment for melanoma.

          -  Presence of brain metastases

          -  Presence or history (<= 5 years) of a second malignancy other than nonmelanoma skin
             cancer or cervical carcinoma in situ

          -  Female subjects who are pregnant or nursing
Clinical trial NCT00393939 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sunitinib malate, taxotere
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Breast cancer with evidence of unresectable locally recurrent, or metastatic disease

          -  Her-2 negative tumors

        Exclusion Criteria:

          -  Patients for whom docetaxel is contraindicated

          -  Clinical presentation of inflammatory carcinoma with no other measurable disease
Clinical trial NCT00190515 (phase 3, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5fu+l-leucovorin, uft+leucovorin
SMILES: [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          1. Pathologically proved colorectal cancer (either adenocarcinoma, mucinous carcinoma, or
             signet-ring cell carcinoma).

          2. Tumor is mainly located in between cecum and upper rectum, excluding that invades to
             lower rectum.

          3. Stage III cancer by General Rules for Clinical and Pathological Studies on Cancer of
             the Colon, Rectum and Anus (6th ed.), excluding si(ai), n(-), M(-).

          4. No synchronous colorectal cancer which invade muscularis propria or deeper.

          5. Tumor resection with D2 or D3 lymph node dissection was performed.

          6. Pathological determination of curability of tumor resection is cur A.

          7. Age at registration is above 20 and below 75 years old.

          8. ECOG Performance status is 0 or 1.

          9. No prior chemotherapy or radiation therapy.

         10. Intake of normal diet and oral drugs is possible.

         11. Major organ function is preserved. WBC>=3,000/mcl, PLT>=100,000/mcl, GOT<=100 IU/L,
             GPT<=100 IU/L, T.Bil <=2.0 mg/dl, Cr<=1.5 mg/dl

         12. Adjuvant chemotherapy can be started within 9 weeks after surgery.

         13. Written informed consent is taken.

        Exclusion Criteria:

          1. Active co-existing malignancy （synchronous or metachronous malignancy whose disease
             free period is within 5 years). Carcinoma in situ is eligible.

          2. Severe postoperative complications which do not resolve until registration.

          3. There is following complication. insulin-controlling or uncontrollable diabetes
             mellitus, uncontrollable hypertension, myocardial infarction within six month or
             unstable angina pectoris, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis,
             severe emphysema

          4. Pregnant or breast-feeding woman.

          5. Difficult to participate with the trial, having mental disorder or psychiatric
             symptoms.

          6. Judged to be inappropriate to register.
Clinical trial NCT02183168 (phase 3, status: completed)
Conditions: spondylitis, ankylosing
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: meloxicam suppository, meloxicam tablet, indomethacin
SMILES: CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O, CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O, COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Active ankylosing spondylitis (pain rated >= 40 mm on a VAS and increased of at least
             30% after nonsteroidal anti-inflammatory drugs (NSAIDs) wash-out)), without peripheral
             arthritis and inflammatory bowel disease

        Exclusion Criteria:

        none
Clinical trial NCT01452776 (phase 3, status: completed)
Conditions: erosive esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: tak-438, tak-438
SMILES: CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1, CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Participants must have successfully completed the preceding phase 3 double-blind study
             (TAK-438/CCT-002: preceding study) and have endoscopically healed EE at Week 2, 4, or
             8 in the preceding study.*

             * "Endoscopically healed EE" is defined as those participants who have endoscopically
             confirmed EE of Grade O as defined by the Los Angeles (LA) Classification Grading
             System.

          2. Outpatient (including inpatient for examination)

        Exclusion Criteria:

          1. Participants with an esophagus-related complication (eosinophilic esophagitis,
             esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis,
             etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or
             physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with
             Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or
             Barrett's esophagus are allowed to be included.

          2. Participants who have received surgery or treatment affecting gastroesophageal reflux
             (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or
             who have a history of surgery of stomach or duodenum (excluding removal of benign
             polyp under endoscopy)

          3. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer
             (mucosal defect with white coating) within 30 days prior to Visit M-1 (initiation of
             study drug administration). However, participants with gastric or duodenal erosions
             are allowed to be included.

          4. Participants with a previous or current history of Zollinger-Ellison syndrome, or
             other gastric acid hypersecretion disorder
Clinical trial NCT00300586 (phase 3, status: completed)
Conditions: stage iv non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: observation, gemcitabine, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented NSCLC (tumor tissue samples will be provided to look for
             assessment of EGFR status with CISH, immunochemistry and mutations) : adenocarcinoma,
             squamous cell carcinoma, large cell carcinoma. A cytological documentation of NSCLC is
             accepted.

          -  Stage IV disease or metastatic relapse in not previously irradiated areas of a NSCLC
             previously treated with surgery or radiation therapy (with a histologically documented
             proof of relapse) or stage III B with documented pleural involvement.

          -  Measurable disease according to the RECIST criteria.

          -  Prior radiotherapy authorized except for irradiation concerning measurable disease.

          -  Age >18 and < 70 years.

          -  PS < 2.

          -  Normal hepatic function : serum bilirubin < 1.5 ULN, SGOT (ASAT) and SGPT (ALAT) < 2,5
             ULN ; in presence of liver metastases, SGOT and SGPT must be < 5 x ULN.

          -  Creatinine clearance > 60 mL/min.

          -  Granulocyte count > 1,5 giga/L, platelet count > 100 giga/L.

          -  Life expectancy > 12 weeks.

          -  Written (signed) informed consent for use of tumors samples.

          -  Written (signed) informed consent to participate in the sudy.

        Exclusion Criteria:

          -  Small cell lung cancer, bronchiolo-alveolar carcinoma, neuro-endocrine carcinoma.

          -  PS > 1.

          -  Prior chemotherapy other than cisplatin-gemcitabine.

          -  Prior therapy with EGFR inhibitor (e.g. monoclonal antibody).

          -  No concomitant therapy with phenytoin, carbamazepine, rifampicine or phenobarbital.

          -  Concomitant radiotherapy except for localized bone irradiation.

          -  Symptomatic brain metastases.

          -  Superior vena cava syndrome.

          -  Any unstable systemic disease : significant cardiovascular disease including
             myocardial infarction within the previous year, active infection, significant hepatic
             or renal disease.

          -  Pre-existing interstitial lung disease.

          -  Any inflammatory changes of the surface of the eyes.

          -  Psychiatric disease with inability to understand the study or to comply with follow-up
             procedures.

          -  Grade > or = 2 peripheral neuropathy.

          -  Any other malignancies within 5 years (except for treated carcinoma in situ of the
             cervix or basal cell skin cancer).

          -  Pregnant or lactating women ; patients with reproductive potential must use effective
             contraception.

          -  Inability to comply with follow-up procedures.
Clinical trial NCT00325403 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: oral treprostinil (ut-15c) sustained release tablets
SMILES: [H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Between 12 and 75 years of age, inclusive.

          -  Body weight at least 40 kg with a Body Mass Index < 45

          -  PAH that is either idiopathic/heritable; associated with repaired congenital
             systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular
             disease; associated with HIV.

          -  Previous testing (e.g., right heart catheterization, echocardiography) consistent with
             the diagnosis of PAH.

          -  Baseline 6-minute walk distance between 200 and 425 meters, inclusive.

          -  Reliable and cooperative with protocol requirements.

        Exclusion Criteria:

          -  Nursing or pregnant.

          -  Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5
             inhibitor, or prostacyclin within 30 days of Baseline.

          -  PAH due to conditions other than noted in the above inclusion criteria.

          -  History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart
             disease, uncontrolled systemic hypertension, or parenchymal lung disease.

          -  Use of an investigational drug within 30 days of Baseline.
Clinical trial NCT00171080 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan, irbesartan
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mild and moderate hypertension defined by a MSSBP ≥ 140 mmHG and < 180
             mmHG at Visits 1 and 2 for treated and untreated patients

          -  Chronic hemodialysis for at least 6 months prior to Visit 1 as substitution therapy.

          -  If treated with epoetin: patients with a stable hematocrit ≤ 40% (± 5%).

        Exclusion Criteria:

          -  Inability to discontinue angiotensin II receptor blockers (ARBs) safely for a period
             of 1 week, as required by the protocol.

          -  Treatment with more than 3 different compounds for the treatment of hypertension at
             Visit 1.

          -  Atrial fibrillation

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00359879 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, exenatide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes.

          -  Have been treated with one of the following treatment regimens for at least three
             months prior to screening: *metformin alone; *sulfonylurea (SU) alone;
             *thiazolidinedione (TZD) alone; *a combination of metformin and SU; *a combination of
             metformin and TZD.

          -  HbA1c between 7.1% and 10.0%, inclusive.

          -  Body Mass Index (BMI) > 25 kg/m^2 and < 45 kg/m^2

        Exclusion Criteria:

          -  Have participated in an interventional, medical, surgical, or pharmaceutical study (a
             study in which an experimental drug, medical, or surgical treatment was given) within
             30 days prior to screening.

          -  Have characteristics contraindicating metformin, SU, or TZD use.

          -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical and inhaled preparations) or have received such therapy within 2
             weeks immediately prior to screening.

          -  Have used any prescription drug to promote weight loss within 3 months prior to
             screening.

          -  Are currently treated (for greater than 2 consecutive weeks) with any of the following
             excluded medications: *insulin within 3 months prior to screening; *alpha-glucosidase
             inhibitors within 3 months prior to screening; *meglitinides within 3 months prior to
             screening; *drugs that directly affect gastrointestinal motility